NASDAQ:TCON - TRACON Pharmaceuticals Stock Price, Forecast & News

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

TRACON Pharmaceuticals Inc (NASDAQ:TCON) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.03. View TRACON Pharmaceuticals' Earnings History.

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for TRACON Pharmaceuticals.

TRACON Pharmaceuticals will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 analysts have issued 12 month price targets for TRACON Pharmaceuticals' shares. Their forecasts range from $7.00 to $18.00. On average, they expect TRACON Pharmaceuticals' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 228.1% from the stock's current price. View Analyst Price Targets for TRACON Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TRACON Pharmaceuticals.

Media stories about TCON stock have been trending very negative on Saturday, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for TRACON Pharmaceuticals.

TRACON Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 71,300 shares, an increase of 30.1% from the January 15th total of 54,800 shares. Based on an average trading volume of 462,000 shares, the short-interest ratio is currently 0.2 days. Currently, 2.1% of the company's stock are sold short. View TRACON Pharmaceuticals' Current Options Chain.

Some companies that are related to TRACON Pharmaceuticals include Idera Pharmaceuticals (IDRA), Curis (CRIS), Organovo (ONVO), Polarityte (PTE), Neon Therapeutics (NTGN), Entera Bio (ENTX), BioCardia (BCDA), Outlook Therapeutics (OTLK), CytRx (CYTR), aTyr Pharma (LIFE), Titan Pharmaceuticals (TTNP), Genetic Technologies (GENE), Aevi Genomic Medicine (GNMX), TrovaGene (TROV) and Enzon Pharmaceuticals (ENZN).

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include SCYNEXIS (SCYX), Verastem (VSTM), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Opko Health (OPK), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), MEI Pharma (MEIP), Progenics Pharmaceuticals (PGNX) and Catalyst Pharmaceuticals (CPRX).

(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

TRACON Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (11.04%), Renaissance Technologies LLC (4.83%) and Puissance Capital Management LP (2.42%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Cross-Border Opportu Puissance, Enterprise Associates 14 New and Mark C Wiggins. View Institutional Ownership Trends for TRACON Pharmaceuticals.

TCON stock was sold by a variety of institutional investors in the last quarter, including Puissance Capital Management LP, NEA Management Company LLC and Renaissance Technologies LLC. View Insider Buying and Selling for TRACON Pharmaceuticals.

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCON stock can currently be purchased for approximately $3.81.

TRACON Pharmaceuticals has a market capitalization of $11.96 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-34,960,000.00 in net income (profit) each year or ($13.00) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe.View Additional Information About TRACON Pharmaceuticals.

The official website for TRACON Pharmaceuticals is http://www.traconpharma.com/.

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]